Journal article

Glial Cells in Glaucoma: Friends, Foes, and Potential Therapeutic Targets

Mariana Y Garcia-Bermudez, Kristine K Freude, Zaynab A Mouhammad, Peter van Wijngaarden, Keith K Martin, Miriam Kolko

FRONTIERS IN NEUROLOGY | FRONTIERS MEDIA SA | Published : 2021

Abstract

Glaucoma is the second leading cause of blindness worldwide, affecting ~80 million people by 2020 (1, 2). The condition is characterized by a progressive loss of retinal ganglion cells (RGCs) and their axons accompanied by visual field loss. The underlying pathophysiology of glaucoma remains elusive. Glaucoma is recognized as a multifactorial disease, and lowering intraocular pressure (IOP) is the only treatment that has been shown to slow the progression of the condition. However, a significant number of glaucoma patients continue to go blind despite intraocular pressure-lowering treatment (2). Thus, the need for alternative treatment strategies is indisputable. Accumulating evidence sugges..

View full abstract